Supplements for article: The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study
Published: 20 September 2024| Version 1 | DOI: 10.17632/9xvwbfz598.1
Contributors:
Amy Paller, , , , , , , , Zhixiao Wang, Description
Supplements for article with title: The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study Journal: Journal of the American Academy of Dermatology
Files
Categories
Atopic Dermatitis, Quality of Life, Quality of Sleep, Patient-Reported Outcome
Funding
Regeneron (United States)
Sanofi (United States)